IL22RA2 and inflammatory bowel disease: This is of particular relevance as the injection of recombinant IL-22 is currently under evaluation in IBD clinical trials (NCT03650413), and it is thus unclear whether the IL-22BP-rich environment created in the ileum could lead to more interference with the biological actions of the drug in involved ileum vs. colon of CD patients.